This site is intended for healthcare professionals
CDK 4/6 banner image
CDK4/6 inhibitors in breast cancer
Declaration of sponsorship

Post-knowledge questions

Declaration of sponsorship
Read time: 5 mins
Last updated:30th Jul 2023
Published:30th Jul 2023

Thank you for completing the knowledge quiz and evaluation form! You will receive your CME accreditation certificate within 5 working days.

1. What is currently the only approved CDK4/6 inhibitor for treating early breast cancer?

The correct answer is B. Abemaciclib.

2. Approval of abemaciclib for use in people with high-risk HR+/HER2− early breast cancer was based on clinical trial data from which study?

The correct answer is D. monarchE.

3. What PARP inhibitor is recommended for people with early breast cancer, BRCA mutation and a high-risk of recurrence?

The correct answer is C. Olaparib.

Thank you for participating in this webinar! Click here to explore our CDK4/6 inhibitors in breast cancer Learning Zone to continue your learning.

Before watching the CDK4/6 inhibitors as adjuvant therapy in early breast cancer webinar, please take a moment to evaluate your current level of knowledge on the topic by participating in this short quiz.

Before watching the CDK4/6 inhibitors as adjuvant therapy in early breast cancer webinar, please take a moment to evaluate your current level of knowledge on the topic by participating in this short quiz.

1. What is currently the only approved CDK4/6 inhibitor for treating early breast cancer?
2. Approval of abemaciclib for use in people with high-risk HR+/HER2− early breast cancer was based on clinical trial data from which study?
3. What PARP inhibitor is recommended for people with early breast cancer, BRCA mutation and a high risk of recurrence?
4. What topics in CDK4/6 inhibitors for treating early breast cancer would you like to learn more about?
Did the event fulfil your expectations?
Was the information balanced and supported by evidence?
Was this event free from commercial bias? 
Was there adequate time for Q&A?
Will you implement what was presented  in your  clinical practice?

How useful was each session?

How useful was each session?

1. Advances with CDK4/6 inhibitors in the EBC treatment landscape
2. Exploring the safety and tolerability of CDK4/6 inhibitors in EBC
3. Panel discussion: Optimal use of CDK4/6 inhibitors in EBC
4. Choosing the right treatment for EBC at high risk of recurrence
5. Panel discussion: Choosing the right treatment for EBC at high risk of recurrence – implementing guideline recommendations
I am happy to be contacted at a future date to share how learnings from this event have affected my clinical practice